A
AsclepiX Therapeutics
Developing therapies to treat ocular diseases
About AsclepiX Therapeutics
AsclepiX Therapeutics is a biotechnology company focused on developing innovative peptide-based therapies for the treatment of retinal vascular diseases and cancer. The company's lead candidate, AXT107, is a synthetic peptide derived from collagen IV protein sequences. AXT107 works by inhibiting the pro-angiogenic VEGFR2 receptor and activating the vessel-stabilizing Tie2 receptor, addressing two key pathways in retinal vascular disease treatment. AsclepiX was founded by researchers from Johns Hopkins University School of Medicine and has since grown under the leadership of experienced biomedical and pharmaceutical executives. The company operates in the biopharmaceutical market, primarily serving patients with unmet medical needs in ocular diseases and oncology. AsclepiX's business model involves the rapid clinical development and commercialization of its novel therapeutics. Revenue is generated through the successful development and potential future sales of its drug candidates.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2023 | $10M | $175M | Rapha Capital Management · Hibiscus BioVentures · Perceptive Advisors | ↗ |
| SERIES AOther financing | Jun 2020 | $35M | $140M | Rapha Capital Management · Perceptive Advisors | — |
Growth signals
Latest recorded traffic for AsclepiX Therapeutics is 430 monthly website visits, down 64.2% over the last three months. AsclepiX Therapeutics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AsclepiX Therapeutics in the Bethesda ecosystem
The AsclepiX Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
TEDCO
Salem Partners
Perceptive Advisors
Rapha Capital Management
Hibiscus BioVentures
Other known investors1 additional known investor
Johns Hopkins University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AsclepiX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AsclepiX Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









